Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease

Shunsaku Nakagawa1, Kumiko Nishihara1, Hitomi Miyata2, Haruka Shinke1, Eri Tomita1, Moto Kajiwara1[a], Takeshi Matsubara2, Noriyuki Iehara2[b], Yoshinobu Igarashi3, Hiroshi Yamada3, Atsushi Fukatsu2[ac], Motoko Yanagita2, Kazuo Matsubara1, Satohiro Masuda1[ad]*

1 Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606–8507, Japan, 2 Department of Nephrology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606–8507, Japan, 3 Toxicogenomics Informatics Project, National Institutes of Biomedical, Innovation, Health and Nutrition, 7-6-8, Saito-Asagi, Ibaraki, Osaka, 567–0085, Japan

[a] Current address: Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, 812–8582, Japan
[b] Current address: Division of Nephrology, Kyoto City Hospital, Nakagyoku, Kyoto, 604–8845, Japan
[ac] Current address: Division of Nephrology, Yachiyo Hospital, Anjo, Aichi, 446–8510, Japan
[ad] Current address: Department of Pharmacy, Kyushu University Hospital, Higashi-ku, Fukuoka, 812–8582, Japan

* satomsdb@pharm.med.kyushu-u.ac.jp

Abstract

In chronic kidney disease (CKD), progressive nephron loss causes glomerular sclerosis, as well as tubulointerstitial fibrosis and progressive tubular injury. In this study, we aimed to identify molecular changes that reflected the histopathological progression of renal tubulointerstitial fibrosis and tubular cell damage. A discovery set of renal biopsies were obtained from 48 patients with histopathologically confirmed CKD, and gene expression profiles were determined by microarray analysis. The results indicated that hepatitis A virus cellular receptor 1 (also known as Kidney Injury Molecule-1, KIM-1), lipocalin 2 (also known as neutrophil gelatinase-associated lipocalin, NGAL), SRY-box 9, WAP four-disulfide core domain 2, and NK6 homeobox 2 were differentially expressed in CKD. Their expression levels correlated with the extent of tubulointerstitial fibrosis and tubular cell injury, determined by histopathological examination. The expression of these 5 genes was also increased as kidney damage progressed in a rodent unilateral ureteral obstruction model of CKD. We calculated a molecular score using the microarray gene expression profiles of the biopsy specimens. The composite area under the receiver operating characteristics curve plotted using this molecular score showed a high accuracy for diagnosing tubulointerstitial fibrosis and tubular cell damage. The robust sensitivity of this score was confirmed in a validation set of 5 individuals with CKD. These findings identified novel molecular markers with the potential to contribute to the detection of tubular cell damage and tubulointerstitial fibrosis in the kidney.

OPEN ACCESS

Citation: Nakagawa S, Nishihara K, Miyata H, Shinke H, Tomita E, Kajiwara M, et al. (2015) Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. PLoS ONE 10(8): e0136994. doi:10.1371/journal.pone.0136994

Editor: Hideharu Abe, Tokushima University Graduate School, JAPAN

Received: April 14, 2015
Accepted: August 11, 2015
Published: August 28, 2015

Copyright: © 2015 Nakagawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All gene expression data files derived with microarray analyses are available from the GEO database (accession numbers GSE66494).

Funding: This work was supported in part by a grant-in-aid for Research on Biological Markers for New Drug Development and Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (08062855 to S. Masuda); by a Funding Program for Next Generation World-Leading Researchers (NEXT Program: LS073 to S. Masuda) initiated by the Council for Science and Technology.
Introduction

Physiological changes in the course of chronic kidney disease (CKD) produce a complex series of outcomes, including loss of kidney function, leading to end-stage renal failure. In CKD, the irreversible and progressive loss of nephrons results in glomerular sclerosis, tubular atrophy, tubulointerstitial fibrosis, and eventually further reductions in nephron numbers. Pathological changes such as tubular cell atrophy and interstitial fibrosis are commonly seen in progressive renal disease, irrespective of the initial etiology; these are cardinal features of CKD [1, 2]. However, the molecular characteristics of these pathological events remain to be fully understood.

Microarray analysis facilitates a genome-wide survey of mRNA transcripts; this approach can be used to study the active biological processes in animal models of renal injury [3, 4] and in human kidney disease [5, 6]. Halloran et al. adapted microarray analysis for renal transplant biopsies, revealing gene expression differences associated with future graft loss or acute kidney injury in renal transplant patients [7, 8]. In addition, renal biopsy microarray data was useful for the prediction of graft survival [9]. Naesens et al. used microarrays to profile renal allografts and identified a molecular signature associated with tubular atrophy and interstitial fibrosis following kidney transplantation [10]. These findings suggested that transcriptional profiling of renal biopsy specimens from CKD patients could assist with diagnosis or therapeutic intervention in this condition. Furthermore, they provided information that may contribute to the identification of useful CKD biomarkers in urine and other body fluids.

We conducted a microarray analysis of renal biopsy specimens from CKD patients in order to identify gene expression differences that associated with the histopathological grade of the biopsies. The studies using a rodent CKD model validated a novel gene set and related this to tubulointerstitial fibrosis and tubular cell injury. In addition, we developed a molecular score using the microarray profiles, and assessed its performance and usefulness for the classification of the grade of tubulointerstitial fibrosis and tubular cell damage.

Materials and Methods

Patients and Biopsies

This study was conducted in accordance with the Declaration of Helsinki and its amendments and was approved by Kyoto University Graduate School and the Faculty of Medicine Ethics Committee. All patients gave their written informed consent. A total of 48 patients with histopathologically confirmed CKD were enrolled into the study as a discovery set. Kidney biopsies were obtained between October 2008 and October 2010. The characteristics of these patients are summarized in Table 1. The patients had various renal diseases that were histologically confirmed as IgA nephropathy (n = 15), membranous nephropathy (n = 7), lupus nephritis (n = 6), minimal change nephrotic syndrome (n = 3), membranoproliferative glomerulonephritis (n = 3), amyloidosis (n = 3), antineutrophil cytoplasmic antibody- related glomerulonephropathy (n = 2), diabetic nephropathy (n = 2), and other nephropathies (n = 6).

In addition to the discovery set, 5 patients were enrolled to a validation set, and kidney biopsies were obtained between May 2012 and June 2012 (Table 2).

All biopsies were assessed by pathologists who were blinded to the results of the microarray studies. Tubular cell damage and tubulointerstitial fibrosis were evaluated and a severity scale of 0–5 was used to grade the pathological lesions observed. The scaling was defined according to the area of tubular lesion or fibrosis: grade 0, 0%; grade 1, up to 10%; grade 2, 10–30%; grade 3, 30–50%; grade 4, more than 50%; grade 5, almost 100%.
RNA Extraction and Microarrays

To stabilize and maintain the integrity of tissue RNA, the obtained biopsy specimens were placed in RNAlater (Life Technologies Corp., Carlsbad, CA, USA) according to the manufacturer’s instruction, and stored at -80°C until further use. Total RNA was isolated from biopsy specimens using an RNeasy micro Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions, and the concentrations of total RNA were measured by spectrophotometry. The quality of total RNA was investigated using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Cyanine-3-labeled complementary (c) RNA was generated using a QuickAmp Labeling Kit (Agilent Technologies). Array hybridization, fluorescence detection, and image acquisition were performed in accordance with the manufacturer’s instructions. In brief, 1.0 μg of each cRNA sample was hybridized to a Whole Human Genome Microarrays (4 × 44K G4112F, Agilent Technologies) at 65°C for 17 h. After the arrays were washed, fluorescent signals were detected using a DNA Microarray Scanner (Agilent Technologies).

Table 1. Characteristics of Patients in the Discovery Set.

| Variables                        | Discovery set (n = 48) |
|----------------------------------|------------------------|
| Age (y)                          | 48.3 ± 18.7            |
| Gender (male/female, n)          | 24 / 24                |
| Serum creatinine (mg/dl)         | 0.96 ± 0.41            |
| Blood urea nitrogen (mg/dl)      | 16.7 ± 8.4             |
| Primary disease (n)              |                        |
| IgA nephropathy                  | 15                     |
| Membranous nephropathy           | 7                      |
| Minimal change nephrotic syndrome| 4                      |
| Membranoproliferative glomerulonephropathy | 3                  |
| Diabetic nephropathy             | 2                      |
| Lupus nephritis                  | 6                      |
| Amyloidosis                      | 3                      |
| ANCA-related glomerulonephropathy| 2                      |
| Others                           | 6                      |
| Histopathology (grade 0–4)       |                        |
| Tubular cell damage grade        | 1.9 ± 1.1 (1–4)        |
| Tubulointerstitial fibrosis grade| 2.1 ± 1.0 (1–4)        |

Values are n or mean ± standard deviation.

ANCA, antineutrophil cytoplasmic antibody.

doi:10.1371/journal.pone.0136994.t001

RNA Extraction and Microarrays

To stabilize and maintain the integrity of tissue RNA, the obtained biopsy specimens were placed in RNAlater (Life Technologies Corp., Carlsbad, CA, USA) according to the manufacturer’s instruction, and stored at -80°C until further use. Total RNA was isolated from biopsy specimens using an RNeasy micro Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions, and the concentrations of total RNA were measured by spectrophotometry. The quality of total RNA was investigated using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Cyanine-3-labeled complementary (c) RNA was generated using a QuickAmp Labeling Kit (Agilent Technologies). Array hybridization, fluorescence detection, and image acquisition were performed in accordance with the manufacturer’s instructions. In brief, 1.0 μg of each cRNA sample was hybridized to a Whole Human Genome Microarrays (4 × 44K G4112F, Agilent Technologies) at 65°C for 17 h. After the arrays were washed, fluorescent signals were detected using a DNA Microarray Scanner (Agilent Technologies).

Table 2. Characteristics of Patients in the Validation Set.

| Subject | Age (y) | Gender | Serum creatinine (mg/dl) | Blood urea nitrogen (mg/dl) | Tubular cell damage grade (0–5) | Tubulointerstitial fibrosis grade (0–5) | Primary disease                      |
|---------|---------|--------|--------------------------|-----------------------------|---------------------------------|----------------------------------------|---------------------------------------|
| A       | 70      | Male   | 9.8                      | 103                         | 4                               | 3                                      | Rapid progressive glomerulonephritis   |
| B       | 64      | Male   | 0.6                      | 23                          | 1                               | 1                                      | Membranous nephropathy                |
| C       | 70      | Male   | 0.9                      | 18                          | 2                               | 2                                      | IgA nephropathy                       |
| D       | 26      | Female | 2.7                      | 32                          | 4                               | 4                                      | Diabetic nephropathy                  |
| E       | 27      | Male   | 1.6                      | 11                          | 5                               | 3                                      | Chronic tubulointerstitial nephritis  |

doi:10.1371/journal.pone.0136994.t002
Microarray Data Analysis

The results of the microarray assays were analyzed using Feature Extraction Software (Agilent Technologies). The raw data sets for the 53 biopsies included in the present study have been deposited at the Gene Expression Omnibus under GSE (accession number: GSE66494). Bad spots were flagged prior to normalizing the assay signals across the experiments with each median. Human adult normal kidney total RNA, purchased from BioChain (Newark, CA), was used as the control. Detectable signals were selected if the mean signal of a feature was greater than that of the corresponding background and if this difference was statistically significant. The ratio of the mean signals from the 48 biopsies in the validation set to those of the control kidney RNA was calculated, and genes with a z-score $> 2.0$ or $< -2.0$ were considered to be up- or down-regulated, respectively. These genes were classified according to their function using MetaCore Software (GeneGo, St. Joseph, MI). Furthermore, the microarray signals for these genes were compared between groups using the Kruskall-Wallis test. Differences were considered to be statistically significant if the probability value ($P$) was $< 0.05$. A molecular score was calculated using the geometric mean of the fold change (versus control kidney RNA) of the values for 5 genes; hepatitis A virus cellular receptor 1 (HAVCR1; also known as Kidney Injury Molecule-1, KIM-1), lipocalin 2 (LCN2; also known as neutrophil gelatinase-associated lipocalin, NGAL), SRY-box 9 (SOX9), WAP four-disulfide core domain 2 (WFDC2), and NK6 homeobox 2 (NKK6-2). This calculation was performed using an adaptation of a previously published method [10]. The area under the receiver operating characteristics curve (AUC-ROC) was calculated and used to assess the performance of this molecular score. Statistical analysis was performed using Prism Version 4.0 software (Graphpad, San Diego, CA).

Animals

A total of 26 C57BL/6 male mice (6-week-old) were purchased from SLC Animal Research Laboratories (Shizuoka, Japan), housed under specific pathogen free conditions at the animal care facility at the Guidelines for Animal Experiments of Kyoto University. All protocols were approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University. The mice were kept in a temperature-controlled (25 ± 2 degree Centigrade) environment with a 12-h light/dark cycle and received a standard diet and water ad libitum. Every efforts made to minimize the number and suffering of animals used. Complete unilateral ureteral obstruction (UUO) was performed as previously described [11]. Under sodium pentobarbital anesthesia, the middle portion of the left ureter was ligated in 2 places and cut between these points. The mice were sacrificed 7 or 14 days after surgery and their kidneys were subjected to subsequent investigations to examine the gene expression profiles after injury (7 mice in each group). Sham-operated rats were used as controls at the same time-points as the rats with UUO (6 mice in each group).

Real-Time PCR

Whole mouse kidney total RNA was extracted with an RNeasy Mini Kit (Qiagen). Total RNA was reverse-transcribed with random hexamers using Superscript II reverse transcriptase (Invitrogen, Life Technologies Corp.) and digested with RNase H (Invitrogen). Real-time PCR was carried out using the Power SYBR Green PCR Master Mix (Applied Biosystems) and an Applied Biosystems StepOnePlus Real-Time PCR System (Applied Biosystems), according to manufacturer’s instructions. The following primers were used: CAGGCATGGATGGCATCA ATCAC and ACTCTAGCTGTGAAGTCAGTGTCG for Acta2; TTCAAGTCTTCAATTGA GGCC and CTCCTGATGTGTGACCGTATAT for Havcr1; CTCAGAACTTTGATCCCTGCC and TCCTTGAGGCCAGAGACTT for Lcn2; AAACCAATTACGGACTGTGTGTT and
TCGCTCGGTCCATTAGGCT for Wfdc2; CGGAGGAAGTCGGTGAAGA and GTCTGGTTTTGGGAGTGGTG for Sox9; and AAGTCTGCCCCGTCTCAAC and GGTCTGCTCGAAA GTCTTCTC for Nkx6-2. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was also measured as an internal control using TaqMan Rodent GAPDH Control Reagent (Applied Biosystems). Data were expressed as mean ± standard deviation of the mean (SD). The data were analyzed statistically by one-way analysis of variance (ANOVA) to account for multiple testing. P values < 0.05 were considered statistically significant. Statistical analysis was performed using Prism Version 4.0 software (Graphpad).

Western blotting
Urine samples collected from the ureters of mice were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride membranes (Merck Millipore, Darmstadt, Germany). Membranes were blocked, washed, and incubated overnight at 4°C with primary antibodies to mouse Kim-1 (Abcam, Cambridge, UK) and mouse Ngal (Santa Cruz Biotechnology, Avenue, CA, USA). The bound antibodies were detected on X-ray film by using enhanced chemiluminescence with horseradish peroxidase (HRP)-conjugated secondary antibodies and cyclic diacylhydrazides (Merck Millipore).

Results
Gene Expression Profiles in Renal Biopsies from CKD Patients
To characterize transcriptional profiles in CKD, we analyzed a discovery set of renal biopsies from 48 different CKD patients (Table 1). First, the differences between the gene expression profiles of these 48 biopsies and that of a control kidney RNA sample were assessed by microarray analysis. Using a z-score cut-off of ± 2.0, we identified 554 down-regulated and 226 up-regulated genes (Fig 1A). We classified these by Gene Ontology using MetaCore software in order to identify key biological functions involved in CKD (Fig 1B). This analysis indicated that genes related to cell cycle progression were significantly increased in renal biopsies of CKD patients. Additionally, levels of transcripts in the erythropoietin pathway and interleukin-2 signaling were decreased in these CKD samples.

We next searched within the 226 up-regulated genes for molecular changes related to tubulointerstitial fibrosis and tubular cell damage. To identify genes associated with kidney pathophysiology, we focused on the transcriptional profiles of patients with primary glomerulonephritis and diabetic nephropathy. Thirty-one patients diagnosed with IgA nephropathy, membranous glomerulonephropathy, minimal change mesangial proliferative glomerulonephropathy, membranoproliferative glomerulonephritis, or diabetic nephropathy were selected for further analysis. The relationship between transcriptional changes and the histopathology grade of each sample was analyzed using the Kruskall-Wallis test. We identified 14 genes showing a significant correlation with tubulointerstitial fibrosis and 9 genes showing a significant correlation with tubular cell damage (P < 0.05; Fig 1C, gray or black circles). Notably, HAVCR1 (KIM-1), LCN2 (NGAL), SOX9, WFD2, and NNX6-2 showed a significant relationship with both tubulointerstitial fibrosis and tubular cell damage (Fig 1C, black circles). We also confirmed that the selection of patient did not significantly affect the results obtained in this analysis (S1 Fig).

Gene Expression Profiles in a Mouse UUO model
To explore whether the mRNA expression levels of the 5 selected genes reflected tubulointerstitial fibrosis or tubular cell damage, we used a rodent UUO model of renal fibrosis (Fig 2A).
Seven and 14 days after surgery, the mRNA expression level of alpha smooth muscle actin (Acta2) was strongly up-regulated in the mouse kidneys, indicating progressive interstitial fibrosis. We found significant up-regulation of Lcn2, Wfdc2, Sox9 and Nkx6-2 in these kidneys. Notably, the expression levels of Wfdc2 and Sox9 were increased as the kidney damage progressed. The expression of Havcr1 also tended to increase in tandem with kidney damage, although this relationship was not statistically significant. On the other hand, the leakage of Ngal (Lcn2) and Kim-1 (Havcr1) proteins in the urine were found after UUO (Fig 2B). These results of the rodent UUO kidney injury model validated those obtained by microarray analysis of human renal biopsies.

Defining Gene Set Scores as Quantitative Parameters for Progressive Tubular Damage

The microarray data provided evidence of an evolution in the expression of HAVCR1, LCN2, SOX9, WFDC2, and NKX6-2 that mirrored the histological progression of tubulointerstitial fibrosis and tubular cell damage (Fig 3A). We therefore explored the usefulness of HAVCR1, NGAL, SOX9, WFDC2, and NKX6-2 as biomarkers for these renal histopathological changes. To develop a gene-based classifier of the severity of tubulointerstitial fibrosis and tubular cell damage, we built a molecular score based on the expression of these 5 genes, as compared with control kidney RNA. This score was calculated as the geometric mean of the fold change (unlogged values) across all probe sets, by adapting a previously published method [10] (Fig 3B). The scores increased with the severity of histopathological changes. In cases with minimal change nephrotic syndrome, 2 patients showed high molecular scores while the histological grades were low. The sensitivity and specificity of this score for histological changes was then evaluated by composite AUC-ROC analysis (Fig 3C). Although the molecular score performed poorly for low-grade histopathology (low AUC values for grade 1 versus grades 2–4), the AUC-ROC analysis showed that it performed well in the discrimination of grades 1–2 versus grades 3–4, and of grades 1–3 versus grade 4.

Molecular Score-Based Prediction of the Severity of Tubular Damage

The microarray analysis of the discovery set resulted in the identification of a molecular score that reflected the extent of tubulointerstitial fibrosis and tubular cell damage. We explored whether this finding was reproduced in an independent validation set (n = 5; Table 2). The expression levels of HAVCR1, LCN2, SOX, WFDC2, and NKX6-2 were evaluated by microarray analysis (Fig 4A). The results showed coordinated expression of these 5 genes in kidney biopsy specimens, at levels comparable to those observed in the discovery set. The molecular score of each biopsy was calculated using the microarray expression data (Fig 4B). Threshold values corresponding to histopathology grade 3 (Threshold I) or grade 4 (Threshold II) were established using the discovery set results (Fig 4B). Using Threshold I, the predicted grades in
Novel Molecular Markers for CKD-Related Damage

A

**Acta2**

|          | Sham | UUO |
|----------|------|-----|
| mRNA relative expression | 5  | 35  |
| Day 7    | 10   | 15  |
| Day 14   | 20   | 30  |

**Havcr1**

|          | Sham | UUO |
|----------|------|-----|
| mRNA relative expression | 0.5 | 2.5 |
| Day 7    | 1.0  | 1.5 |
| Day 14   | 0.5  | 2.0 |

**Lcn2**

|          | Sham | UUO |
|----------|------|-----|
| mRNA relative expression | 100 | 600 |
| Day 7    | 200  | 400 |
| Day 14   | 500  | 1000|

**Wdfc2**

|          | Sham | UUO |
|----------|------|-----|
| mRNA relative expression | 0.5 | 10.0 |
| Day 7    | 1.0  | 15.0|
| Day 14   | 0.5  | 10.0|

**Sox9**

|          | Sham | UUO |
|----------|------|-----|
| mRNA relative expression | 0.5 | 150 |
| Day 7    | 1.0  | 300 |
| Day 14   | 0.5  | 150 |

**Nkx6-2**

|          | Sham | UUO |
|----------|------|-----|
| mRNA relative expression | 0.5 | 10.0 |
| Day 7    | 1.0  | 20.0|
| Day 14   | 0.5  | 20.0|

B

|          | Day 7 | Day 14 |
|----------|-------|--------|
| Sham     |       |        |
| UUO      |       |        |

**Anti-Kim-1**

- 75 kDa

**Anti-Ngal**

- 25 kDa
- 20 kDa
all subjects were consistent with the observed histopathology grades (for both tubulointerstitial fibrosis and tubular cell damage, Table 3). When the molecular score was combined with Threshold II, the predicted grades were consistent with the histopathology grades for tubular cell damage, and the predicted grades of 4 subjects matched their tubulointerstitial fibrosis grades. Furthermore, the scatter plots showed a close correlation between the molecular score and the histopathology grade (Fig 4B).

Discussion

Despite the importance of defining the molecular characteristics of CKD progression, few microarray studies have previously investigated human CKD. In this study, we conducted a microarray analysis of renal biopsies from individuals with CKD to explore their gene expression patterns in relation to relevant histopathological information. This resulted in the identification of gene expression differences that associated with progression of tubulointerstitial fibrosis and tubular cell damage, and these results were validated in a rodent model of CKD. Moreover, the molecular score defined in this study provided a useful marker of the severity of pathological changes.

The present study identified 780 CKD-related differences in gene expression (Fig 1A). The most significantly up-regulated genes were involved in the cell cycle (Fig 1B). This gene cluster included cyclin B2 and cyclin-dependent kinase 1 (CDK1), which are G2/M phase cell cycle regulators. Recent studies reported that the expression levels of cyclin B2 and CDK1 were increased in proliferating tubular epithelial cells from rats with chronic renal failure [3], and that G2/M arrest of proximal tubular epithelial cells was involved in kidney fibrogenesis [12, 13]. Interestingly, our results showed that the expression of CDK1 and cyclin B2 did not correlate with the severity of fibrosis or tubular cell atrophy (Fig 2A), supporting the notion that G2/M arrest in renal cells caused profibrogenic factors to accelerate disease progression in the early phase of CKD.

Hosohata et al. showed that VNN1 could be a biomarker for nephrotoxicant-induced renal injury and the early stage of diabetic nephropathy [14]. In the present study, a gene VNN1 among the CKD-related molecules was also found to be up-regulated in CKD, (8.23 fold increase to control without statistical significance [P > 0.05]). Our data of microarray also showed that the renal expression levels of VNN1 did not correlate with the severity of renal injury, VNN1 would not be an indicator of the progression of renal injury or the therapeutic efficacy.

In this study, a molecular score was calculated from the transcriptional profiles in each biopsy. This score showed a high sensitivity and accuracy for the prediction of tubulointerstitial fibrosis and tubular cell damage (Fig 3). Furthermore, the robustness of the molecular score to predict histological grades was confirmed in the validation set (Fig 4). These findings indicate that the diagnosis of CKD may be improved by using a combination of histology and molecular analyses; this approach may also be valuable for the development of urine or body fluid biomarkers.

Although HAVCR1 (KIM-1) and LCN2 (NGAL) have been characterized as sensitive markers of acute kidney injury [4, 15, 16], recent reports revealed that their kidney expression levels also increased in progressive renal disease [17–20]. The leakage of HAVCR1 and LCN2 into
urine could be detected in IgA nephropathy [21]. In the present study, we found increased expression of HAVCR1 and LCN2 in several forms of CKD, and their expression levels were correlated with the degree of tubulointerstitial fibrosis and tubular cell damage. Our findings offer new support for the development of HAVCR1 and LCN2 as biomarkers for prediction of
the severity of kidney injury in CKD. Further studies are required in order to explore whether the urinary concentrations of HAVCR1 or LCN2 correlate with the severity of histopathological changes.

This is the first report indicating that WFDC2 expression was altered in CKD. Our study revealed that WFDC2 levels increased with progressive interstitial fibrosis and tubular atrophy in human kidneys. WFDC2 encodes a protein with a highly conserved WAP-domain that is a putative serine protease inhibitor [22]. This is a known biomarker for ovarian carcinoma, and WFDC2 protein was identified in tumor tissue [23], urine [24], and serum [25]. A previous microarray study showed that the kidney expression levels of WFDC2 were increased in renal transplant patients [7]. It was recently shown that WFDC2 expression in myofibroblasts from mouse kidneys mediated renal fibrosis after UUO [25]. The authors reported that WFDC2 suppressed the activity of several proteases, including serine proteases and matrix metalloproteinases, and augmented collagen accumulation in the kidney. Taken together, these findings indicate that WFDC2 could represent a candidate biomarker for fibrosis or tubular injury in the damaged kidney.

We further found that expression of NKX6-2 and SOX9 was increased, and that the levels of these transcripts correlated with the extent of histopathology detected in renal biopsies. These genes encode transcription factors that are related to cell differentiation and development of the brain [26] and the pancreas [27–29]. Interestingly, the expression levels of NKX6-2 and SOX9 were reported to be regulated by the sonic hedgehog (SHH) pathway [30, 31]. Taken together with a previous report indicating that the SHH pathway mediated renal fibrosis in mice after UUO and ischemia-reperfusion injury [32], our results suggested that SHH pathway activation was associated with disease progression in CKD patients, and that SHH inhibition could provide an additional therapeutic approach for progressive renal disease.

In summary, the present study investigated the expression profiles of 53 CKD kidney biopsy specimens using microarrays. The expression levels of HAVCR1, LCN2, WFDC2, SOX9, and NKX6-2 were altered in these patients and correlated with the severity of tubulointerstitial fibrosis and tubular cell damage. These findings provide important information for the development of diagnostic tools and therapeutic agents to predict and prevent progressive renal disease.

Supporting Information
S1 Checklist.
(PDF)
S1 Fig. Supplemental information. (A) Distribution of differences in gene expression between control kidney RNA (Control) and RNA extracted from 31 CKD biopsies with primary glomerular disease or diabetic nephropathy. Microarray analysis was performed and genes down-regulated (z-score < -2.0, green) or up-regulated (z-score > 2.0, blue) in CKD are indicated. (B) The numbers of selected genes in the analysis using total biopsies (n = 48) and 31 CKD biopsies were compared. (C) Relationship between P values from Kruskal-Wallis test on tubulointerstitial fibrosis and tubular cell damage in the analysis of 31 CKD biopsies. Each symbol represents one gene. Gray or black circles indicate genes with any P values < 0.05; open circles represent genes with both P values > 0.05.

Acknowledgments
We thank Yumeko Nishino and Yoko Noguchi (Kyoto University Hospital) and Kazumi Letessier (Kyushu University Hospital) for excellent technical assistance.

Author Contributions
Conceived and designed the experiments: SN KN SM. Performed the experiments: SN KN HM HS ET YI HY. Analyzed the data: SN KN HM HS ET MK TM SM. Wrote the paper: SN MK SM. Approved the final version: NI AF MY KM SM.

References
1. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992; 20(1):1–17. PMID: 1621674.
2. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998; 339(20):1448–56. doi: 10.1056/NEJM19981123392007 PMID: 9811921.
3. Nishihara K, Masuda S, Nakagawa S, Yonezawa A, Ichimura T, Bonventre JV, et al. Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. Am J Physiol Renal Physiol. 2010; 298(4):F923–34. doi: 10.1152/ajprenal.00567.2009 PMID: 20071461.
4. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003; 14(10):2534–43. PMID: 12853585.
5. Schwab K, Witte DP, Aronow BJ, Devarajan P, Potter SS, Patterson LT. Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol. 2004; 24(4):438–47. doi: 10.1159/000080188 PMID: 15308877.
6. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003; 349(2):125–38. doi: 10.1056/NEJMoa035585 PMID: 12853585.
7. Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol. 2009; 20(5):1149–60. doi: 10.1681/ASN.2008080863 PMID: 19389445.
8. Mueller TF, Einecke G, Reeve J, Sis B, Mengel M, Jhangri GS, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant. 2007; 7(12):2712–22. doi: 10.1111/j.1600-6143.2007.02005.x PMID: 17941957.
9. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, Famulski KS, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest. 2010; 120(6):1862–72. doi: 10.1172/JCI41789 PMID: 20901945.
10. Naesens M, Khatri P, Li L, Sigdel TK, VITALONE MJ, Chen R, et al. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int. 2011; 80(12):1364–76. doi: 10.1038/ki.2011.245 PMID: 21881554.
11. Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011; 121(10):3981–90. doi: 10.1172/JCI57301 PMID: 21919396.
12. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010; 16(5):535–43. 1p following 143. doi: 10.1038/nm.2144 PMID: 20436483.

13. Wu CF, Chiang WC, Lai CF, Chang FC, Chen YT, Chou YH, et al. Transforming growth factor-β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol. 2013; 182(1):118–31. doi: 10.1016/j.ajpath.2012.09.009 PMID: 23142380.

14. Hosohata K, Ando H, Fujiwara Y, Fujimura A. Vanin-1: a potential biomarker for nephrotoxicant-induced renal injury. Toxicology. 2011; 290(1):82–8. doi: 10.1016/j.tox.2011.08.019 PMID: 21907259.

15. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998; 273(7):4135–42. PMID: 9461608.

16. Vaidya VS, Ozer JS, Dieiterle F, Collings FB, Ramirez V, Troth S, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010; 28(5):748–85. doi: 10.1038/nbt.1623 PMID: 20458318.

17. Nakagawa S, Masuda S, Nishihara K, Inui K. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol. 2010; 79(1):67–76. doi: 10.1016/j.bcp.2009.07.015 PMID: 19660439.

18. Nickolas TL, Forster CS, Sise ME, Barasch N, Solá-Del Valle D, Viltard M, et al. NGAL (Lcn2) monomer sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991; 45(2):350–6. doi: 10.1093/biolre/45.2.350 PMID: 1686187.

19. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007; 212(2):209–17. doi: 10.1002/path.2175 PMID: 17471468.

20. Humphreys BD, Xu F, Sabbisetty V, Grgic I, Naini SM, Wang N, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest. 2013; 123(9):4023–35. doi: 10.1172/JCI45361 PMID: 23979159.

21. Xu PC, Zhang JJ, Chen M, Lv JC, Liu G, Zou WZ, et al. Urinary kidney injury molecule-1 in patients with IgA nephropathy is closely associated with disease severity. Nephrol Dial Transplant. 2011; 26(10):3229–36. doi: 10.1093/ndt/gfr023 PMID: 21402675.

22. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991; 45(2):350–7. PMID: 1686187.

23. Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6):847–53. doi: 10.1038/modpathol.3800612 PMID: 16607372.

24. Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett. 2010; 296(1):43–8. doi: 10.1016/j.canlet.2010.03.013 PMID: 20381233.

25. LeBlue VS, Teng Y, O’Connell JT, Charytan D, Müller GA, Müller CA, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013; 19(6):4023–35. doi: 10.1038/nm.2989 PMID: 23353556.

26. Rodríguez-Seguí S, Akerman I, Ferrer J. GATA believe it: new essential regulators of pancreas development. J Clin Invest. 2012; 122(10):3469–71. doi: 10.1172/JCI65751 PMID: 23006323.

27. Schaffer AE, Freude KK, Nelson SB, Sander M. Nkx6 transcription factors and Ptf1a function as antagonistic lineage determinants in multipotent pancreatic progenitors. Dev Cell. 2010; 18(6):1022–31. doi: 10.1016/j.devcel.2010.05.015 PMID: 20627083.

28. Kessaris N, Pringle N, Richardson WD. Ventral neurogenesis and the neuron-glial switch. Neuron. 2001; 31(5):677–80. PMID: 11567609.

29. Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA, Hanley NA. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. J Biol Chem. 2008; 283(20):14063–71. doi: 10.1074/jbc.M707390200 PMID: 18296708.

30. Bien-Wilner GA, Stankiewicz P, Lupski JR. SOX9cre1, a cis-acting regulatory element located 1.1 Mb upstream of SOX9, mediates its enhancement through the SHH pathway. Hum Mol Genet. 2007; 16(10):1143–56. doi: 10.1093/hmg/ddm061 PMID: 17409199.

31. Ding H, Zhou D, Hao S, Zhou L, He W, Nie J, et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol. 2012; 23(5):801–13. doi: 10.1681/ASN.2011060614 PMID: 22302193.

32. Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipilä P, West KA, et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol. 2012; 180(4):1441–53. doi: 10.1016/j.ajpath.2011.12.039 PMID: 22342522.